Clarion | A Life Sciences Consultancy

We are excited to announce that In Vivo published an article written by Clarion’s medical director, Amama Sadiq MD, MPH et al. This thought piece discusses the key challenges and potential solutions associated with drug development and commercialization in non-alcoholic steatohepatitis (NASH). NASH is an emerging therapeutic area that is currently attracting substantial interest and investment from the biopharma space. A silent epidemic of the western world triggered by a surge in obesity and metabolic risk factors, NASH affects upwards of 10-15 million Americans and (along with its precursor form NAFLD) is estimated to cost the U.S. more than $100B annually. With no approved therapies for this deadly condition, the unmet medical need is exceptionally high. To learn more about Clarion’s unique insights on NASH, please read the full article: http://glassdoor.com/slink.htm?key=vQm8M